Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...
Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results